-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Downgrades Perspective Therapeutics to Neutral, Lowers Price Target to $6

Benzinga·11/25/2024 13:05:27
Listen to the news
B of A Securities analyst Alec Stranahan downgrades Perspective Therapeutics (AMEX:CATX) from Buy to Neutral and lowers the price target from $24 to $6.